Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MDUFA Meeting Postponed Again Due To COVID-19, This Time Indefinitely

Executive Summary

The COVID-19 crisis had already forced the US FDA to postpone its first public meeting on the medical device user-fee negotiations to early next May, which was to be webcast. Now the agency has postponed the meeting indefinitely.

You may also be interested in...

FDA Makes 2nd Attempt At Virtual MDUFA Public Meeting

For the second time in the past few months the US agency has rescheduled a webcast of a public meeting meant to start MDUFA V user-fee negotiations.

Most Premarket Applications Will See 7% Increase Next Year

The US FDA has bumped up the cost of filing for a premarket application in fiscal year 2021 by roughly 7%. That’s slightly higher than the user fee increases under MDUFA IV last year.

AdvaMed Moves MedTech Conference Online

The largest medical device lobby group will host its annual conference online instead of in person. The meeting that had been set to occur over three days in Toronto will now take place in September and end in October.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts